1. Discovery Partnerships with Academia at GSK Carolyn Buser, VP of DPAc BIO 2016 May31-Jun3, 2016 CSPS Conference Vancouver, Canada BIO 2016 From the Valley of Death to the Bridge of Life: Models for de-risking early translational projects from around the world

2. Discovery Partnerships with Academia - DPAc DPAc and GSK Drug discovery and early development expertise Academic Novel target biology and disease expertise Collaborative invention Shared ownership Risk embracing Research milestones Clinical candidate molecules Proof of concept and medicine A discovery unit with the remit to build a rolling pipeline of candidate medicines with an academic partner at the core of each project. 2 Model and organization are unique

3. Key elements of DPAc Focus on the medicine –Collaborative partnerships focused on drug discovery –Starts early (around screening) and finishes with the medicine Undertake the best science –Foundation is in innovative science of the investigator –Access to all GSK drug discovery and development capabilities Share in the investment, share in the reward –Both sides contribute: look for a complementary match of skills where GSK can make a positive contribution to success –Milestone funding with royalties. If GSK stops, then the academic is free to continue and progress 3

4. DPAc collaborations portfolio Target with therapeutic hypothesis, end-to-end, 1:1 partnership, global

5. Approaches to identifying academic collaborators In previous years –Visits to top-tier universities and personal contacts –Discovery Fast Track (DFT) challenges Evolving new approaches –Directed outreach based on publications, presentations, grants –Geographic-specific DFT –Center for Drug Research & Development (CDRD) –Incubator collaborations (e.g., QB3) –Crick Linklabs –Bio Strategy Partners –Platform collaborations with GSK: Open Targets (CTTV), Altius Avalon-GSK DPAc collaboration 5

6. Bio Strategy Partners (Philly centric) : GSK Multi-academia + one pharma collaboration J&J Germinator; GSK signed in May2016 GSK submitted request for proposal from 6 areas, including one from DPAc BioSP coordinates sourcing responses amongst university members Shared funding for ~6 month research project within academic lab 6 Germinator Grants University Members 1/2 Funding Administration 1/2 Funding Assets Targets Technology platforms

7. Avalon Ventures identifies promising new technologies for drug development A GSK and Avalon joint committee decide whether to establish a new company based on technology Both Avalon Ventures and GSK will fund the new companies; GSK’s contributions are linked to milestones “Build to Buy” – the Avalon/GSK collaboration 7 Focus on innovative, novel targets to make therapeutics for unmet medical needs Joint funding of R&D Embed GSK scientists for in-kind research and alignment April 23, 2013  Avalon 1.0: signed in 2Q2013; formed 7 NewCos  Avalon 2.0: signed in 4Q2015, just announced 8 th NewCo

8. Who we are: dpac.gsk.comdpac.gsk.com Duncan Holmes European Head LONDON Mark Bamford Chemistry, LONDON Iain Uings Biology, LONDON John Liddle Chemistry, LONDON Ann Walker Chemistry, LONDON Stephane Huet Biology, PARIS Jeremy Griggs Biology, LONDON Danuta Mossakowska Biology, LONDON Andy Pearce Biology, LONDON Colin Macphee Biology, PHILADELPHIA Andy Pope Biology, PHILADELPHIA Carolyn Buser Global Head, PHILADELPHIA Dan Paone Chemistry, PHILADELPHIA Dedicated team of scientists, each of whom has proven track record in drug discovery Your gateway to GSK’s global expertise and resources Jon Collins Chemistry, NORTH CAROLINA Katherine Widdowson Chemistry, CALIFORNIA Debra Peattie Biology, BOSTON Dave Parry Biology, CALIFORNIA Mike Bishop Chemistry, CALIFORNIA Dennis Yamashita Chemistry, BOSTON Terri Almos BIology, CALIFORNIA Peter Eddershaw DMPK, LONDON Daniel Blom Biology, BOSTON Lori Gavrin Strategy / Chemistry PHILADELPHIA

9. Appendix 900 Month 0000Presentation title in footer

10. What we look for Clear Therapeutic hypothesis A coherent and supportable hypothesis that modulation of target will produce a physiological effect which will be of therapeutic benefit to particular patients Target defined Specific drug target identified, and some understanding of type of pharmacology desired; novelty (Exclusive) enabling expertise Academic partner has know-how and/or expertise essential to progressing the target which is not (readily) found elsewhere Tractability Target knowledge suggests that a drug-like molecule can be generated Disease knowledge suggests that opportunity can be evaluated effectively in the clinic Requirement for GSK contribution GSK has capabilities and expertise which will help progress the project to the next milestone

11. What are GSK’s capabilities?

12. Candidate Selection FTIH Start Clinical POC Launch What is unique about GSK’s DPAc model? Research partnership focused on drug discovery 12 Lead Identification Late Lead Optimization Early Lead Optimization Assay Development Target Feasibility Phase I Phase IIIPhase II Pre-Clinical Early Drug Discovery Launch & Royalties Drug Discovery Initiated Screen Initiated Lead Identified in vitro Lead Identified in vivo Shared Ownership & Oversight Collaborative Invention Staged Pre-Clinical Research Support Development Milestones: Candidate Clinical Compound Selection First Time in Human (FTIH) Clinical Proof of Concept (PoC) Launch of medicine